Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | TEB-17231 |
Synonyms | |
Therapy Description |
TEB-17231 inhibits KRAS, resulting in reduced downstream signaling and potentially leading decreased cell viability and inhibition of tumor growth (Cancer Res (2023) 83 (7_Supplement): 2627). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
TEB-17231 | TEB 17231|TEB17231|YL-17231|YL17231 | KRAS Inhibitor 18 | TEB-17231 inhibits KRAS, resulting in reduced downstream signaling and potentially leading decreased cell viability and inhibition of tumor growth (Cancer Res (2023) 83 (7_Supplement): 2627). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06096974 | Phase I | TEB-17231 | Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS | Not yet recruiting | USA | 0 |